IntelliCyt and FIMM Announce a Collaboration to Advance Personalized Medicine in Cancer Treatment

IntelliCyt, a leading provider of integrated platforms that accelerate drug discovery, antibody screening and immuno-oncology research today announced a collaboration with the Institute for Molecular Medicine Finland (FIMM) at the University of Helsinki to further the development of personalized medicine in cancer treatment. FIMM will utilize IntelliCyt products to test and analyze the effects of approved and emerging investigational oncology compounds on patient cells.

IntelliCyt’s iQue Screener platform is an integrated instrument, software, and reagent system that offers rapid, multiplexed analysis of cell and bead-based samples in 96, 384, and 1536 well plates. The iQue’s proprietary rapid sampling technology uniquely enables rapid assessment of cells in suspension, such as those found in blood and bone marrow, by miniaturizing the assay format, which conserves precious patient samples for further analysis.

Profiling phenotypic and functional endpoints of cells, while simultaneously analyzing secreted proteins through the use of bead-based assays, generates rich information from the fewest numbers of cells. Plates are processed rapidly, and software-assisted automation, analysis, and experiment-level visualization tools help reveal deep insight into complex biology which will allow FIMM to more rapidly evaluate which anti-cancer drugs or combination of drugs would most likely provide the optimal treatment on an individual basis.

 “FIMM has been an IntelliCyt customer since 2014, leveraging the iQue Screener’s capabilities in its groundbreaking work in personalized medicine,” said R. Terry Dunlay, President and CEO of IntelliCyt.

“We are excited to collaborate with FIMM to demonstrate the utility of the iQue Screener platform in predicting individual responses to various cancer treatments, facilitating potential breakthroughs in personalized medicine.”

“We see tremendous potential in applying IntelliCyt’s technology to help analyze drug effects in a high-throughput manner in primary cells from cancer patients” said FIMM-EMBL Group Leader, Krister Wennerberg.

We are continuously looking to develop better ways to predict and assign cancer therapies to patients within our precision cancer medicine program at FIMM. With the iQue Screener, we can significantly improve on existing assays as well as develop entirely new ones that could be predictive of patient responses.